The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study.
Antonio Marcilio Padula Omuro
Consultant or Advisory Role - Roche
Oliver L. Chinot
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Luc Taillandier
No relevant relationships to disclose
Herve Ghesquieres
No relevant relationships to disclose
Carole Soussain
No relevant relationships to disclose
Vincent Delwail
No relevant relationships to disclose
Thierry Lamy
No relevant relationships to disclose
Remy Gressin
No relevant relationships to disclose
Sylvain Choquet
No relevant relationships to disclose
Pierre-Louis Soubeyran
No relevant relationships to disclose
Jean Philippe Maire
No relevant relationships to disclose
Alexandra Benouaich Amiel
Research Funding - Roche
Sophie Lebouvier-Sadot
No relevant relationships to disclose
Emmanuel Gyan
No relevant relationships to disclose
Maryline Barrie
No relevant relationships to disclose
Monica Sierra del Rio
No relevant relationships to disclose
Alberto Gonzalez
No relevant relationships to disclose
Caroline Houillier
No relevant relationships to disclose
Marie-Laure Tanguy
No relevant relationships to disclose
KhĂȘ Hoang-Xuan
No relevant relationships to disclose